Sequential and Combination Therapies of223RaCl2and Prostate-Specific Membrane Antigen Radioligand Therapy

There have been unprecedented strides in theranostics, facilitating the bidirectional “see and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate-specific membrane antigen (PSMA)–targeted, β-emitter 177Lu–labeled radioligand therapy (RLT) as a viable